Literature DB >> 32864815

COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays.

Xueqing Wang1, Yuanfang Guan1,2.   

Abstract

The situation of coronavirus disease 2019 (COVID-19) pandemic is rapidly evolving, and medical researchers around the globe are dedicated to finding cures for the disease. Drug repurposing, as an efficient way for drug development, has received a lot of attention. However, the huge amount of studies makes it challenging to keep up to date with the literature on COVID-19 therapeutic development. This review addresses this challenge by grouping the COVID-19 drug repurposing research into three large groups, including clinical trials, computational research, and in vitro protein-binding experiments. Particularly, to facilitate future drug discovery and the creation of effective drug combinations, drugs are organized by their mechanisms of action and reviewed by their efficacy measured by clinical trials. Providing this subtyping information, we hope this review would serve the scientists, clinicians, and the pharmaceutical industry who are looking at the new therapeutics for COVID-19 treatment.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; clinical trial; computational research; drug repurposing; in vitro protein interaction assay

Mesh:

Year:  2020        PMID: 32864815      PMCID: PMC8049524          DOI: 10.1002/med.21728

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  82 in total

1.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Authors:  X-T Ye; Y-L Luo; S-C Xia; Q-F Sun; J-G Ding; Y Zhou; W Chen; X-F Wang; W-W Zhang; W-J Du; Z-W Ruan; L Hong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

Review 2.  Darunavir for the treatment of HIV infection.

Authors:  Vincenzo Spagnuolo; Antonella Castagna; Adriano Lazzarin
Journal:  Expert Opin Pharmacother       Date:  2018-06-18       Impact factor: 3.889

3.  Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.

Authors:  Aleix Gimeno; Júlia Mestres-Truyol; María José Ojeda-Montes; Guillem Macip; Bryan Saldivar-Espinoza; Adrià Cereto-Massagué; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

4.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Authors:  Yushun Wan; Jian Shang; Rachel Graham; Ralph S Baric; Fang Li
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

5.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

6.  Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Authors:  Ashish Chandwani; Jonathan Shuter
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

7.  Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study.

Authors:  Maryam Enayatkhani; Mehdi Hasaniazad; Sobhan Faezi; Hamed Gouklani; Parivash Davoodian; Nahid Ahmadi; Mohammad Ali Einakian; Afsaneh Karmostaji; Khadijeh Ahmadi
Journal:  J Biomol Struct Dyn       Date:  2020-05-02

8.  Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.

Authors:  Abdo A Elfiky
Journal:  Life Sci       Date:  2020-03-25       Impact factor: 5.037

9.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.

Authors:  Johanna Hansen; Alina Baum; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Elzbieta Wloga; Benjamin O Fulton; Ying Yan; Katrina Koon; Krunal Patel; Kyung Min Chung; Aynur Hermann; Erica Ullman; Jonathan Cruz; Ashique Rafique; Tammy Huang; Jeanette Fairhurst; Christen Libertiny; Marine Malbec; Wen-Yi Lee; Richard Welsh; Glen Farr; Seth Pennington; Dipali Deshpande; Jemmie Cheng; Anke Watty; Pascal Bouffard; Robert Babb; Natasha Levenkova; Calvin Chen; Bojie Zhang; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew Franklin; Sumathi Sivapalasingam; David Chien Lye; Stuart Weston; James Logue; Robert Haupt; Matthew Frieman; Gang Chen; William Olson; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

Review 10.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

Authors:  Qing Ye; Bili Wang; Jianhua Mao
Journal:  J Infect       Date:  2020-04-10       Impact factor: 38.637

View more
  27 in total

Review 1.  Artificial intelligence unifies knowledge and actions in drug repositioning.

Authors:  Zheng Yin; Stephen T C Wong
Journal:  Emerg Top Life Sci       Date:  2021-12-21

2.  Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.

Authors:  Angela Serra; Michele Fratello; Antonio Federico; Ravi Ojha; Riccardo Provenzani; Ervin Tasnadi; Luca Cattelani; Giusy Del Giudice; Pia A S Kinaret; Laura A Saarimäki; Alisa Pavel; Suvi Kuivanen; Vincenzo Cerullo; Olli Vapalahti; Peter Horvath; Antonio Di Lieto; Jari Yli-Kauhaluoma; Giuseppe Balistreri; Dario Greco
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

3.  The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.

Authors:  Eleni Pitsillou; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  J Mol Graph Model       Date:  2022-04-18       Impact factor: 2.942

Review 4.  Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2.

Authors:  Nilesh Gajanan Bajad; Swetha Rayala; Gopichand Gutti; Anjali Sharma; Meenakshi Singh; Ashok Kumar; Sushil Kumar Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-14

5.  Drug repurposing for COVID-19 via knowledge graph completion.

Authors:  Rui Zhang; Dimitar Hristovski; Dalton Schutte; Andrej Kastrin; Marcelo Fiszman; Halil Kilicoglu
Journal:  J Biomed Inform       Date:  2021-02-08       Impact factor: 8.000

Review 6.  The Interface of Therapeutics and Genomics in Cardiovascular Medicine.

Authors:  E F Magavern; J C Kaski; R M Turner; A Janmohamed; P Borry; M Pirmohamed
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-02       Impact factor: 3.727

Review 7.  The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies.

Authors:  Vaishali P Waman; Neeladri Sen; Mihaly Varadi; Antoine Daina; Shoshana J Wodak; Vincent Zoete; Sameer Velankar; Christine Orengo
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

Review 8.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises.

Authors:  Natesh Singh; Bruno O Villoutreix
Journal:  Comput Struct Biotechnol J       Date:  2021-04-26       Impact factor: 7.271

9.  A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework.

Authors:  Raul Pérez-Moraga; Jaume Forés-Martos; Beatriz Suay-García; Jean-Louis Duval; Antonio Falcó; Joan Climent
Journal:  Pharmaceutics       Date:  2021-04-02       Impact factor: 6.321

10.  Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.

Authors:  Chaitra Prabhakara; Rashmi Godbole; Parijat Sil; Sowmya Jahnavi; Shah-E-Jahan Gulzar; Thomas S van Zanten; Dhruv Sheth; Neeraja Subhash; Anchal Chandra; Akshatha Shivaraj; Patricia Panikulam; Ibrahim U; Vijay Kumar Nuthakki; Theja Parassini Puthiyapurayil; Riyaz Ahmed; Ashaq Hussain Najar; Sai Manoz Lingamallu; Snigdhadev Das; Bhagyashri Mahajan; Praveen Vemula; Sandip B Bharate; Parvinder Pal Singh; Ram Vishwakarma; Arjun Guha; Varadharajan Sundaramurthy; Satyajit Mayor
Journal:  PLoS Pathog       Date:  2021-07-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.